J2020
J2020 – Injection, linezolid, 200 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 17 NDCs crosswalked per 200 MG $2.268/unit ASP+6%
📋 J2020 summary
J2020 is a HCPCS Level II J-code used to bill linezolid, 200 mg, billed per 200 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J2020: Linezolid-D5W*, Zyvox, Linezolid
Code J2020
Billing unit 200 MG Payment limit $2.268/unit NDC-Crosswalk 17
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ2020
DescriptorInjection, linezolid, 200 mg
Billing unit200 MG
Payment limit / unit$2.268
Est. ASP / unit$2.140 est.
Mapped NDCs17
Data periodQ3 2026
Last updated2026-08-20
💊 About Linezolid DRUG GUIDE
Linezolid — available as Zyvox and in generic forms — is used to treat infections caused by certain drug-resistant Gram-positive bacteria.
It is approved for adults and children for nosocomial pneumonia (hospital-acquired lung infection), community-acquired pneumonia, complicated skin and skin structure infections (including diabetic foot infections, but only when bone infection is not also present), uncomplicated skin and skin structure infections, and vancomycin-resistant Enterococcus faecium infections.It is important to know that linezolid does not work against Gram-negative bacteria.
If a Gram-negative infection is also present or suspected, a separate antibiotic must be started right away.
Linezolid should only be used for infections that are confirmed or strongly suspected to be caused by bacteria, to help prevent antibiotic resistance.
Clinical overview from our editorial drug guide for Linezolid. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$2.268
Est. ASP / unit
$2.140 est.
Est. after 2% sequester
$2.223
HCPCS dosage
200 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, linezolid, 200 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeN — No maintenance this year
Effective date2018-01-01
Date added2002-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J2020 = 200 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J2020 WITH EST. MEDICARE PAY
17 NDCs map to J2020. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($2.268/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00009-4992-02 | Zyvox | Pfizer | — | — | 30 | $68.04 | — | — | CMS ASP |
| 00009-5137-04 | Zyvox | Pfizer | — | — | 10 | $22.68 | — | — | CMS + PDAC |
| 00009-5140-04 | Zyvox linezolid 600 mg/300mL INJECTION, SOLUTION | Pharmacia | 10 BAG in 1 BOX (0009-5140-04) / 300 mL i... | 600 mg/300mL | 30 | $68.04 | — | ● Active | CMS + PDAC |
| 00009-7807-02 | Zyvox linezolid 600 mg/300mL INJECTION, SOLUTION | Pharmacia | 10 BAG in 1 BOX (0009-7807-02) / 300 mL i... | 600 mg/300mL | 30 | $68.04 | — | ● Active | CMS ASP |
| 00143-9534-10 | Linezolid 600 mg/300mL INJECTION, SOLUTION | Hikma | 10 POUCH in 1 BOX (0143-9534-10) / 1 BAG... | 600 mg/300mL | 30 | $68.04 | — | ● Active | CMS + PDAC |
| 00781-3433-95 | Linezolid 600 mg/300mL INJECTION, SOLUTION | Sandoz | 10 BAG in 1 CARTON (0781-3433-95) / 300 m... | 600 mg/300mL | 30 | $68.04 | — | ● Active | CMS + PDAC |
| 25021-0169-87 | Linezolid | Sagent | — | — | 30 | $68.04 | — | — | CMS ASP |
| 55150-0242-51 | Linezolid 600 mg/300mL INJECTION, SOLUTION | Eugia | 10 POUCH in 1 CARTON (55150-242-51) / 1 B... | 600 mg/300mL | 30 | $68.04 | — | ● Active | CMS + PDAC |
| 57664-0683-57 | Linezolid 600 mg/300mL INJECTION, SOLUTION | Sun | 10 BAG in 1 BOX (57664-683-57) / 300 mL i... | 600 mg/300mL | 30 | $68.04 | — | ● Active | CMS + PDAC |
| 63323-0713-13 | Linezolid 2 mg/mL INJECTION, SOLUTION | Fresenius | 10 BAG in 1 CASE (63323-713-13) / 300 mL... | 2 mg/mL | 30 | $68.04 | — | ● Active | CMS + PDAC |
| 66794-0219-43 | Linezolid 600 mg/300mL INJECTION, SOLUTION | Piramal | 10 BAG in 1 CARTON (66794-219-43) / 300 m... | 600 mg/300mL | 30 | $68.04 | — | ● Active | CMS + PDAC |
| 66794-0236-43 | Linezolid 600 mg/300mL INJECTION | Piramal | 10 BAG in 1 CARTON (66794-236-43) / 300 m... | 600 mg/300mL | 30 | $68.04 | — | ● Active | CMS + PDAC |
| 57664-0683-31 | LINEZOLID (INNER PACK,LATEX-FREE) 2 MG/1 ML | Unknown | — | — | 0.01 | $0.02 | — | — | PDAC |
| 00009-5140-01 | ZYVOX (P.C.) 2 MG/ML | Unknown | — | — | 0.01 | $0.02 | — | — | PDAC |
| 67457-0843-30 | LINEZOLID (10X300ML BAGS,PF) 600 MG/300 ML | Unknown | — | — | 0.01 | $0.02 | — | — | PDAC |
| 00409-4883-01 | LINEZOLID 2 MG/ML | Unknown | — | — | 0.01 | $0.02 | — | — | PDAC |
| 00009-5137-01 | ZYVOX (P.C.) 2 MG/ML | Unknown | — | — | 0.01 | $0.02 | — | — | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2025 (Q1-Q4)
Total Part B spend
$2.2K
Claims
105
Beneficiaries
51
Spend / beneficiary
$43.52
Spend / claim
$21.14
Where J2020 ranks among Part B drugs · 2025 (Q1-Q4) · neighbors ±5
Total spending — #861 of 918
#856
FLUPHENAZINE HCL J2679
$2.9K
#857
DAUNORUBICIN HCL J9150
$2.7K
#858
CANCIDAS* J0637
$2.6K
#859
PROTAMINE SULFATE J2720
$2.5K
#860
RHOPHYLAC J2791
$2.4K
#861
LINEZOLID-D5W* J2020
$2.2K
#862
METHOTREXATE* J8610
$2.2K
#863
DAPTOMYCIN-0.9% NACL J0874
$2.2K
#864
MANNITOL(J2151) J2151
$2.2K
#865
BENZTROPINE MESYLATE J0515
$2.1K
#866
BACLOFEN(J0476)* J0476
$2.1K
Total claims — #789 of 918
#784
FIBRYGA J7177
115
#785
APHEXDA J2277
112
#786
RUCONEST J0596
111
#787
EPYSQLI Q5151
111
#788
GAMIFANT J9210
108
#789
LINEZOLID-D5W* J2020
105
#790
CORIFACT J7180
105
#791
ALPHANATE J7186
103
#792
ZALTRAP J9400
102
#793
SHELTER DM MATRIX PE... Q4346
102
#794
PREHEVBRIO 90759
101
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (1)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2025 (Q1-Q4) | $2.2K | 51 | 105 | $43.52 | $21.14 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$825.76
Medicare paid
$781.67
Submitted services
13,575
Denial rate
98.1%
Allowed / service
$3.23
Submitted charges
$286.4K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J2020 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J2020
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
17 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2025
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J2020 billing FAQ
What is HCPCS code J2020?
J2020 is a HCPCS Level II J-code used to bill Injection, linezolid, 200 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J2020?
One unit of J2020 represents 200 MG. Report the number of units equal to the dose administered divided by 200 MG.
How many units of J2020 should I bill?
Divide the dose administered by the code's unit size (200 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J2020?
The Medicare Part B payment limit is $2.268 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $2.223 per unit. Payment limits are revised quarterly.
Which NDCs bill under J2020?
17 NDCs currently map to J2020 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J2020 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.